NurExone’s ExoPTEN Shows Promise for Glaucoma Treatment

EnerSpar Corp. (TSE:NRX) has released an update.

NurExone Biologic Inc. has announced promising preliminary results from a study on ExoPTEN, its product aimed at optic nerve recovery, showing restoration of vision in animal models. The study indicates potential for treatment in the glaucoma market, which affects over 3 million people in the U.S. alone. These findings lay the groundwork for further research and potential future application in human patients.

For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.